Compagnie Lombard Odier SCmA’s Intellia Therapeutics NTLA Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,000	Closed	-$94.9K	–	601
2023 Q3	$94.9K	Hold	3,000	–	–	﹤0.01%	362
2023 Q2	$122K	Buy	3,000 +1,500	+100%	+$60.8K	﹤0.01%	333
2023 Q1	$55.9K	Hold	1,500	–	–	﹤0.01%	433
2022 Q4	$52K	Hold	1,500	–	–	﹤0.01%	471
2022 Q3	$84K	Sell	1,500 -450	-23%	-$27.9K	﹤0.01%	415
2022 Q2	$101K	Hold	1,950	–	–	﹤0.01%	376
2022 Q1	$142K	Buy	1,950 +450	+30%	+$38.1K	﹤0.01%	347
2021 Q4	$177K	Hold	1,500	–	–	﹤0.01%	382
2021 Q3	$201K	Sell	1,500 -1,500	-50%	-$227K	﹤0.01%	356
2021 Q2	$486K	Sell	3,000 -282,520	-99%	-$22M	0.01%	229
2021 Q1	$22.9M	Buy	285,520 +279,520	+4,659%	+$18.8M	0.51%	43
2020 Q4	$326K	Sell	6,000 -4,000	-40%	-$145K	0.01%	279
2020 Q3	$199K	Hold	10,000	–	–	0.01%	284
2020 Q2	$210K	Hold	10,000	–	–	0.01%	262
2020 Q1	$122K	Hold	10,000	–	–	0.01%	279
2019 Q4	$147K	Buy	10,000 +2,000	+25%	+$27.8K	0.01%	278
2019 Q3	$107K	Hold	8,000	–	–	﹤0.01%	302
2019 Q2	$131K	Hold	8,000	–	–	0.01%	282
2019 Q1	$137K	Buy	8,000 +1,000	+14%	+$14.9K	0.01%	317
2018 Q4	$96K	Hold	7,000	–	–	﹤0.01%	333
2018 Q3	$200K	Hold	7,000	–	–	0.01%	294
2018 Q2	$192K	Hold	7,000	–	–	0.01%	289
2018 Q1	$148K	Sell	7,000 -7,000	-50%	-$172K	0.01%	337
2017 Q4	$270K	Buy	14,000 +7,000	+100%	+$162K	﹤0.01%	358
2017 Q3	$174K	Buy	7,000 +2,500	+56%	+$47.1K	0.01%	383
2017 Q2	$72K	Hold	4,500	–	–	﹤0.01%	473
2017 Q1	$63K	Buy	4,500 +1,500	+50%	+$20.1K	﹤0.01%	512
2016 Q4	$39K	Hold	3,000	–	–	﹤0.01%	638
2016 Q3	$51K	Hold	3,000	–	–	﹤0.01%	677
2016 Q2	$64K	Buy	+3,000	New	+$79.8K	﹤0.01%	629

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Compagnie Lombard Odier SCmA's NTLA Position: Q4 2023 in Review

Compagnie Lombard Odier SCmA sold out of Intellia Therapeutics (NTLA) in Q4 2023, closing a stake of 3,000 shares — an estimated $94.9K sold.

Compagnie Lombard Odier SCmA first reported a position in NTLA in Q2 2016 and held it in 30 quarters. The position peaked at $22.9M in Q1 2021. 292 funds tracked by Wall St. Rank hold NTLA as of Q4 2023.

Compagnie Lombard Odier SCmA reported no remaining Intellia Therapeutics position as of Q4 2023 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 3,000 Intellia Therapeutics shares in Q4 2023, an estimated $94.9K.
Compagnie Lombard Odier SCmA first reported a position in Intellia Therapeutics in Q2 2016 and held it in 30 quarters.
Compagnie Lombard Odier SCmA's Intellia Therapeutics position peaked at $22.9M in Q1 2021.
292 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2023.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q4 2023, filed 16 Jan 2024.